Lancet Haematology

Papers
(The H4-Index of Lancet Haematology is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?544
Towards reparatory measures: blood donation, health systems, and men who have sex with men439
In the trenches233
Prioritising health equity alongside donation safety – Authors' reply214
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?206
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries192
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?143
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3141
Correction to Lancet Haematol 2023; 10: e333–45138
Correction to Lancet Haematol 2024; 11: e114–26136
MRD-guided treatment cessation in multiple myeloma135
Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria125
Zanubrutinib-associated ecchymotic lesions114
Optimising communication to patients with venous thromboembolism: development of a provider toolkit104
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts102
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial97
Blood cell defence against pathogens91
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA89
Blood deserts: a vision to tackle blood inaccessibility84
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study83
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past82
Extensively distributed erythema nodosum in VEXAS syndrome81
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study81
Bedside art is good medicine80
International Society on Thrombosis and Haemostasis Congress 202380
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm77
Be compliant or compromise?77
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia76
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia76
Production and supply of blood products in Brazil76
Eltrombopag–cyclosporin A in treating severe aplastic anaemia75
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study72
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis72
Methodological challenges in the development of endpoints for myelofibrosis clinical trials69
USAID's enduring impact on anaemia management must be preserved68
Anaemia in a time of climate crisis65
Correction to Lancet Haematol 2023; 10: e433–4464
Coexisting genetic abnormalities and thrombocytopenia64
Correction to Lancet Haematol 2025; 12: e294–30363
Rituximab versus active surveillance in patients with follicular lymphoma62
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health61
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study60
Sickle cell disease in India: current status and progress56
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial56
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran55
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective 55
Oreofe Odejide—aiming to raise the bar in haematology care54
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial53
Universal health coverage for children with cancer53
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial52
Could improving mental health disorders help increase cancer survival?52
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment51
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial51
0.54275703430176